NYAM’s historic annual awards recognizing leadership and contributions in the medical and health-related fields to be presented virtually on September 27,.
The OHDSI community and SNOMED have formalized their long-time relationship with a 5-year collaborative agreement that will benefit both user communities.
TrialX Software to Power Space Health Research with the Launch of the Inspiration4 Mission pr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr.com Daily Mail and Mail on Sunday newspapers.
Patients on ACE inhibitors, ARBs, don t have higher COVID-19 risk medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
E-Mail
NEW YORK, NY (Dec. 17, 2020) While the COVID-19 pandemic left the world searching for answers during the earliest stages of the pandemic, one immediate healthcare concern regarded the use of certain antihypertensives and whether they posed increased risks to patients with hypertension.
A new study by global collaborators within the Observational Health Data Sciences and Informatics (OHDSI) community found that there was no increased risk of COVID-19 diagnosis, hospitalization, or subsequent complications for users of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) among an international cohort of more than 1.1 million patients using antihypertensives.
The study was published today in